Status: Recruiting
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Participants needed: 900
Trial details
Phase: Phase 2Age: 18-80Biological sex: MaleType: InterventionalSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolUpdated: Aug 16, 2022Locations: 1
Eligibility criteria
All patients must have been histologically diagnosed of prostate cancer and must... [+5]
Patients with neuroendocrine, small cell, or sarcoma-like pathologic features ar... [+8]